Zhenghu Chen
Yangtze River Pharmaceutical Group (China)(CN)Shanghai University of Medicine and Health Sciences(CN)
Publications by Year
Research Areas
Neuroblastoma Research and Treatments, Ubiquitin and proteasome pathways, Cancer, Hypoxia, and Metabolism, Advanced biosensing and bioanalysis techniques, Cell death mechanisms and regulation
Most-Cited Works
- → USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis(2013)196 cited
- → USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase(2014)174 cited
- → Neutralizing Aptamers Block S/RBD‐ACE2 Interactions and Prevent Host Cell Infection(2021)122 cited
- → A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways(2014)103 cited
- → Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity(2016)80 cited
- → Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis(2016)51 cited
- → mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling